Evidence map›Paper›PMID 35992245›Full record

ArticleJTO clinical and research reports2022

Comparing Survival in Patients With Lung Cancer With and Without a History of Common Autoimmune Disease.

Demitrios Dedousis, Anastasia N Vassiliou, Shufen Cao, Deepthi Yammani, Ravi K Kyasaram, John Shanahan, Melissa C Keinath, Annie L Zhang, Melinda L Hsu, Pingfu Fu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Demitrios DedousisDepartment of Internal Medicine/Case Western Reserve University, UH Cleveland Medical Center, University Hospitals, Cleveland, Ohio.
Anastasia N VassiliouCase Western Reserve University, Cleveland, Ohio.
Shufen CaoDepartment of Population and Quantitative Health Sciences, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio.
Deepthi YammaniUH Seidman Cancer Center, UH Cleveland Medical Center, University Hospitals, Cleveland, Ohio.
Ravi K KyasaramUH Seidman Cancer Center, UH Cleveland Medical Center, University Hospitals, Cleveland, Ohio.
John ShanahanUH Seidman Cancer Center/Case Western Reserve University, Case Comprehensive Cancer Center, UH Cleveland Medical Center, University Hospitals, Cleveland, Ohio.
Melissa C KeinathDepartment of Pathology, UH Cleveland Medical Center, University Hospitals, Cleveland, Ohio.
Annie L ZhangDepartment of Internal Medicine/Case Western Reserve University, UH Cleveland Medical Center, University Hospitals, Cleveland, Ohio.
Melinda L HsuDepartment of Hematology and Oncology, UH Seidman Cancer Center, UH Cleveland Medical Center, University Hospitals, Cleveland, Ohio.
Pingfu FuDepartment of Population and Quantitative Health Sciences, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio.
Afshin DowlatiDepartment of Hematology and Oncology/Case Western Reserve University, Case Comprehensive Cancer Center, UH Seidman Cancer Center, UH Cleveland Medical Center, University Hospitals, Cleveland, Ohio.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Autoimmune disease has both a predisposing and a protective effect toward malignancy. Though studies have investigated the risk of malignancy in patients with autoimmune disease, there is limited research on how autoimmunity affects survival. Methods: This study compared survival in patients with lung cancer with and without autoimmune disease. Patients with lung cancer were culled from the Surveillance, Epidemiology, and End Results Medicare databases (2007-2014), and autoimmune diseases were identified using diagnosis codes. Results: The overall prevalence of investigated autoimmune diseases among the 112,445 patients was 22.7%. Overall survival (OS) ( Conclusions: The prevalence of rheumatoid arthritis, inflammatory bowel disease, and systemic lupus erythematous was highly enriched compared with the general population. The improvement in OS and CSM was larger in NSCLC than in SCLC, suggesting a larger role for the immune system in NSCLC. Alternate explanations for the improved survival include lead time bias, better access to health care, and a survival or autoimmunity-inducing genetic factor.

Indexed as

Autoimmune disease prevalenceNSCLCSCLCSEER databaseSurvival

Identifiers

PMID35992245
PMCPMC9386095

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.